Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Jazz Pharmaceuticals completed the $820 million acquisition of Actio Biosciences, adding ABS-1230, a clinical-stage precision therapy for KCNT1-related epilepsy, to its rare disease pipeline. ABS-1230 has FDA Fast Track, Rare Pediatric Disease, and Orphan Drug designations and showed promising early clinical results in reducing seizures in children.

This Wire brief sits within Fusion42's coverage of Biotech.